Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01534715 · ClinicalTrials.gov registry record · Phase 1
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
A Phase 1 study of Chronic Lymphocytic Leukemia and Lymphoma, Non-Hodgkin, sponsored by ImmunoGen.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 7
- Study locations
NCT01534715 is a Phase 1 study of Chronic Lymphocytic Leukemia and Lymphoma, Non-Hodgkin that has completed, run by ImmunoGen. The registered enrollment target is 49 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (73% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT01534715, a Phase 1 study of Chronic Lymphocytic Leukemia and Lymphoma, Non-Hodgkin, has completed, sponsored by ImmunoGen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).
Conditions Studied
Interventions
- DRUG IMGN529
Study Locations (7)
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan-Kettering Cancer Center - New York
Ohio
- Ohio State University - Columbus
Tennessee
- Sarah Cannon Research Institute - Nashville
Texas
- CTRC at UTHSCSA - San Antonio
Wisconsin
- Medical College of Wisconsin - Milwaukee
Other
- Oncology Institute of Southern Switzerland - Bellinzona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2012-01 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01534715
The ClinicalTrials.gov registry entry for NCT01534715 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (73% lower). The listed sponsor is ImmunoGen, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which IMGN529 is the first listed.
NCT01534715 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Massachusetts, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT01534715 about?
NCT01534715 is a clinical study titled "IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia". The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).
What is the current status of trial NCT01534715?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2012-01. Estimated completion is 2016-07.
What conditions does trial NCT01534715 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin.
What interventions are being tested in trial NCT01534715?
The interventions under investigation include: IMGN529 (DRUG).
Who is sponsoring clinical trial NCT01534715?
This trial is sponsored by ImmunoGen, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01534715 being conducted?
This trial has 7 study locations across Massachusetts, New York, Ohio, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.